Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cyclerion Therapeutics Inc (CYCN)

Cyclerion Therapeutics Inc (CYCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?

Cyclerion Therapeutics (CYCN) shares more than quadrupled on Wednesday after announcing a merger with Korsana Biosciences, a privately held biotech firm focused on Alzheimer’s. In its press release, CYCN confirmed that the combined entity will rebrand as Korsana Biosciences and trade on the Nasdaq under the new ticker symbol “KRSA.”

At the time of writing, Cyclerion stock is trading at nearly 6x its price in early February. 

Fundamentals

See More
  • Market Capitalization, $K 25,043
  • Shares Outstanding, K 3,925
  • Annual Sales, $ 2,000 K
  • Annual Income, $ -3,060 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.89
  • Price/Sales 2.93
  • Price/Cash Flow N/A
  • Price/Book 0.54

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.28 +380.47%
on 03/03/26
8.48 -27.48%
on 04/01/26
+4.85 (+373.08%)
since 03/02/26
3-Month
1.03 +499.06%
on 02/09/26
8.48 -27.48%
on 04/01/26
+4.81 (+358.96%)
since 01/02/26
52-Week
1.03 +499.06%
on 02/09/26
8.48 -27.48%
on 04/01/26
+3.54 (+135.63%)
since 04/02/25

Most Recent Stories

More News
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

NEW YORK , April 2, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

CYCN : 6.15 (-3.61%)
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?

Cyclerion stock soared on a merger agreement with privately held Korsana Biosciences. But there are ample reasons for disciplined investors to avoid chasing the rally in CYCN shares.

CYCN : 6.15 (-3.61%)
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...

CYCN : 6.15 (-3.61%)
Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , April 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Cyclerion (NASDAQ: CYCN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

CYCN : 6.15 (-3.61%)
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases Korsana’s lead...

CYCN : 6.15 (-3.61%)
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders...

CYCN : 6.15 (-3.61%)
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase...

CYCN : 6.15 (-3.61%)
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025...

CYCN : 6.15 (-3.61%)
Cyclerion Therapeutics Advances Growth Strategy with Key License Amendments and Asset Evaluations

Cyclerion Therapeutics updates on strategic growth, leveraging sGC assets, reducing expenses, and progressing with asset evaluations and agreements.Quiver AI SummaryCyclerion Therapeutics, Inc. has provided...

CYCN : 6.15 (-3.61%)
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

CYCN : 6.15 (-3.61%)

Business Summary

Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. The company's product pipeline consists of Olinciguat, Praliciguat and IW-6463 which are in...

See More

Key Turning Points

3rd Resistance Point 9.15
2nd Resistance Point 7.95
1st Resistance Point 7.05
Last Price 6.15
1st Support Level 4.95
2nd Support Level 3.75
3rd Support Level 2.85

See More

52-Week High 8.48
Last Price 6.15
Fibonacci 61.8% 5.63
Fibonacci 50% 4.75
Fibonacci 38.2% 3.87
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.